SUNNYVALE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a number one client genetics and analysis firm, at this time appointed Daniel Chu as Chief Product Officer.
Previous to becoming a member of 23andMe, Chu served as Chief Product Officer for Waymo, the place he launched the world’s first industrial totally autonomous ride-hailing service. He oversaw the product administration, program administration, consumer expertise design and analysis, industrial design, product information science and technique groups for the corporate. Earlier than Waymo, Chu led the Google Maps platform product group, which included the Google Maps API, some of the standard APIs out there.
“Dan is a collaborative, data-driven chief that may construct client services at scale. He has confirmed he can navigate extremely technical and controlled environments for client dealing with merchandise. We’re excited to welcome Dan as we construct out our genomic well being platform,” stated Anne Wojcicki, Chief Government Officer and Co-Founding father of 23andMe.
“I’m excited to be becoming a member of a founder-led, mission-driven firm that’s centered on utilizing information to revolutionize well being, wellness and analysis,” stated Chu. “23andMe has helped deliver genetics into the mainstream and I stay up for becoming a member of the corporate because it embarks on remodeling healthcare to ship a extra personalised expertise. 23andMe has a passionate group constructing impactful services that actually have the potential to assist folks dwell longer, more healthy lives.”
Chu holds Bachelor of Science (BS) and Bachelor of Arts (BA) levels from Stanford College, a Grasp of Enterprise Administration (MBA) diploma from Harvard Enterprise College, and a Grasp of Public Administration (MPA) diploma from Harvard Kennedy College.
23andMe is a genetics-led client healthcare and therapeutics firm empowering a more healthy future. For extra data, please go to www.23andMe.com.
This press launch accommodates forward-looking statements inside the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, together with, with out limitation, statements relating to the long run efficiency of 23andMe’s companies in client genetics and therapeutics and the expansion and potential of its proprietary analysis platform. All statements, apart from statements of historic truth, included or included on this press launch, together with statements relating to 23andMe’s technique, monetary place, funding for continued operations, money reserves, projected prices, plans, and targets of administration, are forward-looking statements. The phrases “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “could,” “may,” “ought to,” “potential,” “doubtless,” “tasks,” “predicts,” “proceed,” “will,” “schedule,” and “would” or, in every case, their unfavorable or different variations or comparable terminology, are supposed to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. These forward-looking statements are predictions primarily based on 23andMe’s present expectations and projections about future occasions and numerous assumptions. 23andMe can not assure that it’s going to truly obtain the plans, intentions, or expectations disclosed in its forward-looking statements and you shouldn’t place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements contain various dangers, uncertainties (lots of that are past the management of 23andMe), or different assumptions that will trigger precise outcomes or efficiency to vary materially from these expressed or implied by these forward-looking statements. The forward-looking statements contained herein are additionally topic typically to different dangers and uncertainties which are described once in a while within the Firm’s filings with the Securities and Alternate Fee, together with below Merchandise 1A, “Danger Elements” within the Firm’s most up-to-date Annual Report on Kind 10-Okay and in its subsequent reviews on Types 10-Q and 8-Okay. The statements made herein are made as of the date of this press launch and, besides as could also be required by regulation, 23andMe undertakes no obligation to replace them, whether or not because of new data, developments, or in any other case.
A photograph accompanying this announcement is on the market at https://www.globenewswire.com/NewsRoom/AttachmentNg/515f0e84-3766-467c-91ec-e93d42b4411a